In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.

Company Name	Title of Study	Update Date
Bayer Taiwan Co., Ltd.	XATOC – Xarelto + Acetylsalicylic Acid: Treatment patterns and Outcomes across the disease Continuum in patients with CAD and/or PAD	2022-07-20
Bayer Taiwan Co., Ltd.	RAPIT/ Safety and Effectiveness of Xofigo® (Radium-223 dichloride) in Routine Clinical Practice Settings in Taiwan)	2022-07-07
Bayer Taiwan Co., Ltd.	XARETO / Xarelto® for the prevention of stroke and non-central nervous systemic embolism in non-valvular atrial fibrillation with REnal impairment in Taiwanese population.	2022-06-28
Pfizer	A Phase 4, Open-Label, Randomized study of two Inotuzumab ozogamicin dose levels in adult patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia eligible for Hematopoietic Stem cell Transplantation and who have Risk factor(s) for veno-occlusive Disease.	2022-01-20
AbbVie Biopharmaceuticals GmbH Taiwan Branch	Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD)	2021-09-06
AbbVie Biopharmaceuticals GmbH Taiwan Branch	Real World Treatment Patterns and Clinical Outcomes in Unfit AML Patients Receiving First Line Systemic Treatment or Best.	2021-05-31
Pfizer	TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS OUTCOMES SURVEY (THAOS): A GLOBAL, MULTI-CENTER, LONGITUDINAL, OBSERVATIONAL SURVEY OF PATIENTS WITH DOCUMENTED TRANSTHYRETIN (TTR) MUTATIONS OR WILD-TYPE TTR AMYLOIDOSIS	2021-03-02
Pfizer	Thromboembolic and Bleeding Risks of Apixaban, Rivaroxaban and Dabigatran versus Warfarin in Patients with Non-Valvular Atrial Fibrillation	2021-03-02
Pfizer	Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan, A Retrospective NHIA Database Analysis	2020-11-24
Bayer Taiwan Co., Ltd.	AURIGA / An observationAl stUdy pRogram to InvestiGate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting.	2020-06-19